Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Patients taking Eli Lilly & Co. (LLY)?s experimental diabetes drug dulaglutide lost weight and had side effects that were manageable, the company said today after releasing more data from three final-stage clinical trials.
Lilly released top-line results from the company-sponsored trials last year, when it reported more patients taking the therapy had blood glucose levels indicating their disease was under control than those given Merck (MRK) & Co.?s top-selling drug Januvia and Bristol-Myers (BMY) Squibb Co.?s Byetta. The data released today had details of those results, as well as side effect and weight-loss information.
http://www.bloomberg.com/news/2013-06-22/lilly-s-experimental-diabetes-drug-helps-reduce-weight.html
Lilly released top-line results from the company-sponsored trials last year, when it reported more patients taking the therapy had blood glucose levels indicating their disease was under control than those given Merck (MRK) & Co.?s top-selling drug Januvia and Bristol-Myers (BMY) Squibb Co.?s Byetta. The data released today had details of those results, as well as side effect and weight-loss information.
http://www.bloomberg.com/news/2013-06-22/lilly-s-experimental-diabetes-drug-helps-reduce-weight.html